Acute Myeloid Leukemia Excellence Forum

Acute Myeloid Leukemia

Excellence Forum

Leaders in the field sharing authoritative insights and institutional best practices.

Interview

Dr Pettit Highlights Whether Low-Risk MDS Is Really Low Risk

10/20/2021

Kristen Pettit, MD, discusses MDS and highlights if low-risk MDS is really low risk. These data were presented at the virtual 2021 LL&M Congress.

Kristen Pettit, MD, discusses...

10/20/2021

Oncology

Interview

Dr Walker Discusses Chemo Plus Oblimersen in Patients With AML

10/01/2021

Alison R. Walker, MD, discusses the background, findings, and clinical significance of a phase 3 trial on chemotherapy with or without oblimersen in older patients with AML.

Alison R. Walker, MD, discusses...

10/01/2021

Oncology

Videos

Dr Abdelhakim Discusses NGS To Detect MRD Before HSCT in AML

08/31/2021

Haitham Abdelhakim, MD, discusses a meta-analysis on using NGS to detect MRD in patients with AML undergoing HSCT; the data of which were presented at the virtual 2021 ASCO Annual Meeting.

Haitham Abdelhakim, MD,...

08/31/2021

Oncology

Laura Agresta, MD, of Michigan State University

Videos

Dr Agresta Talks Venetoclax, CPX-351 for Young Patients With R/R AML

08/20/2021

Laura Agresta, MD, discusses a study on venetoclax and CPX-351 in young patients with relapsed/refractory AML; these data were presented at the virtual 2021 ASCO Annual Meeting.

Laura Agresta, MD, discusses a...

08/20/2021

Oncology

Videos

Ilaria Michelozzi, PhD, Discusses CAR T-Cell Targeting in AML

07/26/2021

Dr Michelozzi discusses therapeutic targeting using CAR T-cells in patients with AML.

Dr Michelozzi discusses...

07/26/2021

Oncology

Conference Insider

Harry Erba, Md, PhD, Discusses Treatment Shift in AML with Maintenance Therapy

07/16/2021

Harry Erba, MD, PhD, discusses how the treatment paradigm for AML has changed with maintenance therapy.

Harry Erba, MD, PhD, discusses...

07/16/2021

Oncology

Videos

Mark Levis, MD, PhD, Discusses FLT3 Inhibition in Relapsed/Refractory AML

06/05/2021

Dr Levis discusses a study examining FF-10101-01, an irreversible FLT3 inhibitor, in patients with relapsed/refractory AML, which was presented at the 2021 ASCO Annual Meeting.

Dr Levis discusses a study...

06/05/2021

Oncology

Richard Stone, Dana-Farber Cancer Institute, Harvard Medical School, Boston, Massachusetts

Interview

Richard Stone, MD, on Updates in the Treatment of High-Risk AML

05/19/2021

Richard M. Stone, MD, recently shared updates on the treatment of high-risk AML at the Second Summit of the Americas on Immunotherapies for Hematologic Malignancies.

Richard M. Stone, MD, recently...

05/19/2021

Oncology

Interview

Molly Schroeder, PhD, on WGS as an Alternative to Cytogenetics in AML, MDS

04/22/2021

Dr Schroeder spoke on the findings and significance of a study on whole genome sequencing as an alternative to cytogenetic analysis in myeloid cancers.

Dr Schroeder spoke on the...

04/22/2021

Oncology

Videos

Dr Koehne Talks Hot Topics in Hematology at the Miami Cancer Institute Summit

03/22/2021

Guenther Koehne, MD, discusses highlights from the Second Summit of the Americas on Immunotherapy for Hematologic Malignancies.

Guenther Koehne, MD, discusses...

03/22/2021

Oncology

Recent News

News

Intraoperative Radiation Therapy May Improve Survival For Certain Patients With Recurrent Cervical or Endometrial Cancer

11/14/2024

Allison Casey ;

According to a retrospective study, there was an appreciable survival gain for well-selected patients with recurrent or persistent endometrial or cervical cancer who receive intraoperative radiation therapy.

According to a retrospective...

11/14/2024

Oncology

News

Amrubicin Plus Irinotecan Demonstrates Promising Efficacy, Safety for Chemotherapy-Naïve Patients With Extensive-Disease Small Cell Lung Cancer

11/14/2024

Stephanie Holland ;

According to results from the phase 2 LC 08-01 trial, amrubicin plus irinotecan demonstrated promising efficacy and safety among chemotherapy-naïve patients with extensive-disease small cell lung cancer.

According to results from the...

11/14/2024

Oncology

News

Addition of Bempegaldesleukin to Nivolumab Does Not Benefit Cisplatin-Ineligible Patients With First-Line Advanced Urothelial Carcinoma

11/13/2024

Stephanie Holland ;

Results from the phase 2 PIVOT-10 trial demonstrated that the addition of bempegaldesleukin to first-line nivolumab did not improve outcomes for cisplatin-ineligible patients with locally advanced or metastatic urothelial carcinoma.

Results from the phase 2...

11/13/2024

Oncology

News

Mirdametinib for Adult and Pediatric Patients With Neurofibromatosis Type 1 With Plexiform Neurofibromas

11/12/2024

Allison Casey ;

According to a phase 2b trial, mirdametinib demonstrated significant confirmed objective response rates with deep and durable reductions of volume of target plexiform neurofibromas and clinically meaningful improvements to health-related...

According to a phase 2b trial,...

11/12/2024

Oncology

News

Epirubicin Plus Cyclophosphamide and Docetaxel Reduces Long-Term Risk of Recurrence for Patients With TOP2A Normal Early Breast Cancer

11/12/2024

Stephanie Holland ;

According to final results from the DBCG 07-READ trial, the addition of epirubicin to cyclophosphamide and docetaxel reduced long-term risk of breast cancer recurrence among patients with TOP2A normal early breast cancer.

According to final results from...

11/12/2024

Oncology

News

Pembrolizumab Plus Chemotherapy For Patients With High-Risk Endometrial Cancer

11/11/2024

Allison Casey ;

According to results from a phase 3 trial, pembrolizumab plus chemotherapy did not improve DFS among patients with high-risk endometrial cancer. However, there may be a benefit among patients with mismatch report-deficient disease.

According to results from a...

11/11/2024

Oncology

FDA Approval

FDA Grants Approval to Obecabtagene Autoleucel for R/R B-Cell Precursor Acute Lymphoblastic Leukemia

11/08/2024

On November 8, 2024, the FDA approved CD19-directed genetically modified autologous T cell immunotherapy obecabtagene autoleucel for the treatment of patients with relapsed/refractory B-cell precursor acute lymphoblastic leukemia.

On November 8, 2024, the FDA...

11/08/2024

Oncology

News

Naporafenib in Combination With Rineterkib or Tremetinib for KRAS- or BRAF-Mutant Non-Small Cell Lung Cancer

11/07/2024

Allison Casey ;

While naporafenib plus rineterkib and naporafenib plus trametinib both had acceptable safety profiles, antitumor activity was limited among patients with KRAS-/BRAF-mutant non-small cell lung cancer.

While naporafenib plus...

11/07/2024

Oncology

News

Addition of Concurrent Thoracic Radiotherapy to First-Line TKI Therapy Improves Survival for Patients With EGFR-Mutated Non-Small Cell Lung Cancer

11/06/2024

Stephanie Holland ;

According to results from a phase 3 trial, the addition of concurrent thoracic radiotherapy to first-line icotinib improved survival among patients with EGFR-mutated oligo-organ metastatic non-small cell lung cancer.

According to results from a...

11/06/2024

Oncology

News

Ipilimumab After PD-1 Inhibition Failure Among Patients With Metastatic Melanoma

11/05/2024

Allison Casey ;

A single-center real-world study found the use of ipilimumab in the second-line was an effective therapy for patients with metastatic BRAF/NRAS-wildtype metastatic melanoma without brain metastases.

A single-center real-world study...

11/05/2024

Oncology